Published on: Sep 18, 2017 at ESMO

ESMO 2017 Press Release: Pembrolizumab: Promising Response Rate in Pretreated Metastatic Gastric Cancer

By : ESMO

Breaking news was just released at the European Society for Medical Oncology Congress in Madrid: new data in phase two of the KEYNOTE-059 trial of Pembrolizumab (Keytruda) shows promising results in treating metastatic gastric cancer.

Read More
SHARE